Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health, sold 16,514 shares of Class A Common Stock for approximately $44,492 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, the CEO of Medicare Advantage for Clover Health Investments, Corp. (CLOV), reported a sale of company stock.
• The transaction involved the disposition of 16,514 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $2.69 per share, with prices ranging from $2.65 to $2.72.
• The total value of the shares sold amounts to approximately $44,492.86.
• This sale was executed on October 17, 2025, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Reynoso on March 13, 2025.
• Following this transaction, Mr. Reynoso beneficially owns 2,955,226 shares of Class A Common Stock directly.

Sentiment

Score: 4

Explanation: The sentiment is mildly negative due to an insider sale, though mitigated by the relatively small number of shares sold compared to total holdings and the pre-arranged nature of the Rule 10b5-1 plan, which suggests a planned financial event rather than a reaction to new negative information.

Negatives

• The sale of shares by a key executive, even under a pre-arranged plan, can sometimes be interpreted by the market as a signal of reduced confidence or a belief that the stock is fully valued.

Risks

• Potential negative market sentiment or investor perception regarding insider selling, which could exert downward pressure on the company's stock price.
• While the sale was pre-planned, it still represents a reduction in the executive's direct ownership stake.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as sales by executives, are routinely monitored by investors as they can provide insights into management's perception of the company's valuation or future prospects. The use of a Rule 10b5-1 plan indicates a pre-scheduled sale, which is a common practice for executives to manage personal finances while avoiding accusations of trading on material non-public information.

Comparison to Industry Standards

• Not directly applicable as this filing reports an individual insider transaction rather than company performance metrics or operational results. Insider trading activity is generally compared against historical patterns for the specific company and broader market trends in executive stock transactions.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially impacting investor confidence and short-term stock price movements.
• Employees: No direct impact mentioned, but general market sentiment can indirectly affect employee morale if stock performance is a factor in compensation.

Key Dates

Recommendation

While an insider sale is generally a negative signal, the transaction represents a relatively small percentage of the CEO's total holdings and was conducted under a pre-arranged Rule 10b5-1 plan. This suggests a planned personal financial event rather than an immediate reaction to new adverse company information. Therefore, this single transaction alone does not warrant a strong 'sell' recommendation, but it also doesn't provide a 'buy' signal. A 'hold' recommendation is appropriate, advising investors to monitor future company performance and broader market trends.

Keywords

Clover Health, CLOV, Jamie L. Reynoso, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Executive Compensation, Medicare Advantage